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[1228 words]  
Compared with the universal acceptance of antenatal steroids as an inexpensive, safe and 
highly effective way of enhancing neonatal survival and reducing morbidity in preterm infants, 
the use of steroids after birth has been more controversial,1 and there remains uncertainty 
about which steroid to use, indications, safety and dosage. 
 
Neonatal bronchopulmonary dysplasia (BPD) or chronic lung disease is the most common 
neonatal complication following extremely preterm (<28 weeks gestational age) or extremely 
low birthweight (<1000 g) birth and around half of these infants are receiving supplemental 
oxygen at 36 weeks post menstrual age. Chronic respiratory morbidity remains with the child 
throughout life. Children with more severe neonatal lung disease have poorer respiratory 
function in early adolescence2 and likely also to have respiratory morbidity in adult life3. The 
consequences of BPD are not confined to the respiratory system but associated with other 
neonatal morbidities, such as persistence of the ductus arteriosus and increased risk of 
neonatal sepsis. Children with neonatal BPD have higher rates of neurologic morbidity at follow 
up, poor postnatal growth, and evidence of increased cardiovascular risk. Preventing BPD is 
thus a priority in neonatal medicine and is likely to have benefit beyond only respiratory 
outcomes. 
 
Despite the high prevalence of BPD among the increasingly immature population of infants 
surviving preterm birth, no drugs have been licensed to prevent this condition. Vitamin A was 
studied specifically as a preventive agent and showed a significant reduction in the frequency of 
BPD4. However, the injections are painful and limited long-term outcome data are available; 
because of this vitamin A has not found widespread acceptance by the neonatal community. A 
trial evaluating the safety of neonatal caffeine treatment demonstrated reduction in rates of 
BPD,5 together with reassuring safety data at 2 and 5 years of age6, and is now used in clinical 
practice. Set against these examples, knowledge of the early and late effects of neonatal steroid 
administration to prevent or treat BPD remains unclear. 
 
The use of dexamethasone in the second or third week after birth, initially successful in 
weaning infants from mechanical ventilation, was subject to enthusiastic overuse in the late 
1990s. Following development of concern about adverse long-term neurodevelopmental 
outcomes,7 there was a rapid decline in use of dexamethasone and an increase in the 
prevalence of BPD. Over time, more information about this intervention became available, and 
a 2014 systematic review suggested that using corticosteroids after 7 days of age may reduce 
neonatal mortality without increasing the risk of long-term neurologic disability, although the 
power of any of the included studies to demonstrate safety was limited8. Attempts to study 
lower doses of dexamethasone, seemingly as effective as the higher doses investigated, have 
failed to date due to under-recruitment,9 even though many clinicians now use such a regimen. 
Other clinicians have used hydrocortisone in short courses, rather than dexamethasone, and 
anecdotally claim it to be as effective, but this use is not based on robust trial evidence10.  
 
Along with this rescue approach for infants with established severe respiratory disease, other 
investigators have studied the early use of steroids in 2 situations – to prevent BPD and to 
reverse hypotension. These are very different aims. However, given the anxiety about the 
potential long-term effects from the use of postnatal steroids, it would seem incumbent on all 
trials to provide high-quality follow-up data and to power such studies to demonstrate that the 
use of steroids, for either indication, is safe. In one early trial, nearly half of the survivors after a 
3-day course of dexamethasone appear to have developed cerebral palsy, compared with 18% 
in the control group11. However, most of the studies have been too small to determine safety, 
even if they provided long-term outcome data. Determining long-term safety is often forgotten 
in the design of neonatal trials, but it is of utmost importance.  Few trials of early 
administration of neonatal steroids have reported outcomes beyond 2 years, yet there is 
evidence of potential long-term harm in the 2 largest trials carried out in the 1990s, both using 
dexamethasone either as a 3 or 28 day course12.  
 
In this issue of JAMA, Baud and colleagues report important and reassuring data from a trial of 
early neonatal low-dose hydrocortisone to prevent chronic lung disease or BPD, detailing 
secondary safety outcomes at 2 years of age13. The Early Low-Dose Hydrocortisone to Improve 
Survival without Bronchopulmonary Dysplasia in Extremely Preterm Infants (PREMILOC) trial is 
important as it is, to date, the largest investigation of hydrocortisone to prevent BPD and 
previously reported a 9 percentage point increase in survival without BPD at 36 weeks (primary 
outcome)14, a similar effect size to vitamin A and caffeine. This outcome was achieved using the 
lowest dose of hydrocortisone yet investigated.  In the current report, a high rate of follow up 
was achieved (379 of 406 survivors; 93%) at a median 22 months corrected age.  The rates of 
potential neonatal complications of steroids were not increased in the group exposed to 
hydrocortisone. Although the trial was not powered for secondary outcomes, there was no 
significant difference in the frequency of pre-specified neurodevelopmental impairment (NDI) 
between the infants who received hydrocortisone and those who received placebo 
(hydrocortisone group: no NDI, 73%; mild NDI, 20%; moderate-to-severe NDI, 7%; placebo 
group: no NDI, 70%, mild NDI, 18%; moderate-to-severe NDI, 11%; P=0.37).  The posthoc 
outcome of mean global developmental index was also not significantly different between 
groups (91.7 in hydrocortisone group vs 91.4 in placebo group), and the 95% confidence 
interval for the difference (0.3, 95% CI, -2.7 to 3.4) reassuringly was within the 5-point minimal 
clinically important difference. Growth and respiratory outcomes were similarly distributed 
between the 2 groups. 
 
Thus, early use of low-dose hydrocortisone holds promise as an intervention to prevent BPD.  
However, the systematic review12 found steroid-related short-term complications, including 
gastrointestinal bleeding and perforation, although those complications were not seen in the 
current trial. A re-evaluation of early neonatal therapy is warranted.  Other groups are 
encouraged to confirm the findings of the PREMILOC trial, using a very low dose of 
hydrocortisone and powering their studies to investigate safety outcomes. The PREMILOC 
investigators are planning later outcome studies at 5-7 years of age.  Until those and other trials 
are completed, the value of early hydrocortisone to safely prevent BPD appears promising but 
remains unclear.  
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